Major Rating Factors:
Weak overall results on stability tests (0.9 on a scale of 0 to 10) including weak risk diversification, weak results on operational trends and negative cash flow from operations for 2024. The largest net exposure for one risk is excessive at 20.8% of capital. Fair profitability index (3.6) with operating losses during 2020, 2022, 2023, 2024 and the first six months of 2025. Average return on equity over the last five years has been poor at -1.8%. History of adequate reserve strength (6.7) as reserves have been consistently at an acceptable level.
Other Rating Factors:
Strong long-term capitalization index (10.0) based on excellent current risk adjusted capital (severe and moderate loss scenarios), despite some fluctuation in capital levels. Superior liquidity (9.2) with ample operational cash flow and liquid investments.
Stability Factors:
D - Limited diversification of general business, policy, and/or investment risk.
F - Negative cash flow.
T - Significant trends in critical asset, liability, income or expense items.
Principal Lines of Business:
Med mal (100.0%)
Licensed in:
AZ
Principal Investments:
Cash (40.2%), investment grade bonds (38.4%), common stock (21.5%)
Ratios
Premium to Surplus
Reserve to Surplus
--
1-Year Reserve Development
2-Year Reserve Development
Expense Ratio
Combined Ratio
Cash From Underwriting
Net Premium Growth
Investments in Affiliates
--
Corporate Info
Group Affiliation
None
Investment Rating
--
Company Address
3101 North Central Avenue
Phoenix, AZ 85012
Phoenix, AZ 85012
Phone Number
(602) 200-6900
NAIC Number
12166
Website
--
Largest Affiliates
No affiliate information available.